![]() |
市場調查報告書
商品編碼
1906696
2021-2031年锝-99m市場規模及預測、全球及區域佔有率、趨勢和成長機會分析報告涵蓋範圍:按應用、最終用戶和地理分類Technetium-99m Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application, End User and Geography |
||||||
在美國,锝-99m市場正穩步擴張,這主要得益於先進的醫療基礎設施、患者意識的提高以及核醫學影像技術的廣泛應用。醫院和診斷中心正增加對SPECT/CT等混合影像系統的投資,以提高診斷準確性和工作流程效率。心血管疾病、癌症和骨骼疾病的日益普遍,推動了心臟病學、腫瘤學和骨骼掃描等領域對基於锝-99m影像技術的需求。包括碲化鎘鋅(CZT)偵測器和先進重建軟體在內的技術創新,進一步提高了影像質量,縮短了掃描時間,並最大限度地減少了患者的輻射暴露。強大的鉬-99/锝-99m發生器供應鏈確保了锝-99m放射性藥物的穩定供應,從而支持其常規臨床應用。此外,對用於腫瘤和神經成像的新型示蹤劑的持續研究有望拓展其臨床應用,進一步鞏固锝-99m作為美國醫療保健市場首選診斷同位素的主導地位。
中東和非洲(MEA)的锝-99m(Tc-99m)市場正崛起為一個極具成長潛力的地區,這主要得益於醫療基礎設施投資的增加、核子醫學意識的提高以及慢性病患病率的上升。沙烏地阿拉伯、阿拉伯聯合大公國、南非和埃及等國處於領先地位,其政府積極支持先進診斷技術的應用。醫院和診斷中心正在擴展核醫能力,引入SPECT/CT等混合影像系統,進而提高心血管、腫瘤、骨骼和其他器官特異性應用的診斷精度。
該地區心血管疾病、癌症和呼吸系統疾病負擔日益加重,導致對基於Tc-99m的影像檢查的需求不斷成長。對醫療基礎設施的投資,特別是對私人醫院和專科診斷中心的投資,正在推動先進影像設備的安裝。此外,與全球供應商和技術供應商的合作也幫助該地區的醫療機構獲得最新的影像技術創新,包括碲鋅鎘(CZT)偵測器和先進的影像重建軟體。
儘管面臨設備成本高昂和訓練有素的人員有限等挑戰,但中東和非洲(MEA)市場正受益於政府推動醫療現代化的各項舉措,包括改善放射性藥物的獲取途徑和加強監管支持。可靠的鉬-99/锝-99m產生器的供應確保了穩定的供應,從而能夠用於常規診斷。隨著患者意識的提高、醫療投資的增加以及現代影像技術的普及,預計未來幾年中東和非洲锝-99m市場將保持穩定持續成長。
The Technetium-99m Market size was US$ 4.54 billion in 2024 and is expected to reach US$ 6.03 billion by 2031. The Technetium-99m market size is estimated to register a CAGR of 4.2% during 2025-2031.
The U.S. Technetium-99m market is expanding steadily, driven by advanced healthcare infrastructure, high patient awareness, and widespread adoption of nuclear medicine imaging. Hospitals and diagnostic centers are increasingly investing in hybrid imaging systems such as SPECT/CT to enhance diagnostic accuracy and workflow efficiency. The growing prevalence of cardiovascular diseases, cancer, and bone disorders is fueling demand for Tc-99m-based imaging across cardiology, oncology, and bone scans. Technological innovations, including cadmium-zinc-telluride (CZT) detectors and advanced reconstruction software, are further improving image quality, reducing scan times, and minimizing radiation exposure for patients. Strong Mo-99/Tc-99m generator supply chains ensure consistent availability of Tc-99m radiopharmaceuticals, supporting routine clinical use. In addition, ongoing research into novel tracers for tumor and neurological imaging is expected to expand clinical applications, reinforcing Tc-99m's dominance as the preferred diagnostic isotope in the U.S. healthcare market.
The Middle East and Africa (MEA) Technetium-99m (Tc-99m) market is emerging as a region of significant growth potential, driven by increasing investment in healthcare infrastructure, rising awareness of nuclear medicine, and growing prevalence of chronic diseases. Countries such as Saudi Arabia, UAE, South Africa, and Egypt are at the forefront, with governments actively supporting the adoption of advanced diagnostic technologies. Hospitals and diagnostic centers are expanding nuclear medicine capabilities to include hybrid imaging systems like SPECT/CT, improving diagnostic precision for cardiovascular, oncology, bone, and other organ-specific applications.
The rising burden of cardiovascular diseases, cancer, and respiratory disorders in the region is increasing demand for Tc-99m-based imaging procedures. Investments in healthcare infrastructure, particularly in private hospitals and specialized diagnostic centers, are supporting the installation of advanced imaging equipment. Additionally, collaborations with global suppliers and technology providers are helping regional facilities access the latest imaging innovations, including CZT detectors and advanced image reconstruction software.
Despite certain challenges such as high equipment costs and limited trained personnel, the MEA market is benefiting from growing government initiatives promoting healthcare modernization, including improved access to radiopharmaceuticals and enhanced regulatory support. The availability of reliable Mo-99/Tc-99m generators ensures consistent supply, enabling routine diagnostic use. With increasing patient awareness, healthcare investments, and adoption of modern imaging technologies, the MEA Technetium-99m market is expected to experience steady and sustained growth over the coming years.
Lantheus Holdings Inc; Curium; Jubilant Radiopharma; NorthStar Medical Radioisotopes, LLC; Sun RadioPharma (Sun Pharmaceutical Industries, Inc.); NTP Radioisotopes SOC Ltd; Cardinal Health Inc; Medi-Radiopharma; Eckert & Ziegler AG; and Isotope JSC are among the key Technetium-99m market players that are profiled in this market study.
The overall Technetium-99m market size has been derived using both primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the EMEA Technetium-99m market size. The process also helps obtain an overview and forecast of the market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain analytical insights. This process includes industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the EMEA Technetium-99m market.